Price
No data yet.
Social Signal Score
Analyst Ratings
33 analystsRevenue
$214.00M+192692.79%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Emil D. Kakkis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,371
- Beta
- 0.32
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -5.28
Financials
Revenue
$214.00M+192692.8%Net Income
$-92.00MEBITDA
$-61.00MFree Cash Flow
$-98.00MEPS (diluted)
$-0.90Shares Outstanding (diluted)
101.90M+157.6%Operating Expenses
$255.00MCash & Debt
$292.00MRevenue by Segment (annual)
$673.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $673.00M | $-575.00M | $-5.83 |
| 2024 | $560.23M | $-569.18M | $-6.29 |
| 2023 | $434.25M | $-606.64M | $-8.25 |
| 2022 | $363.33M | $-707.42M | $-10.12 |
| 2021 | $351.41M | $-454.02M | $-6.70 |
| 2020 | $271.03M | $-186.57M | $-3.07 |
| 2019 | $103.71M | $-402.73M | $-7.12 |
| 2018 | $51.49M | $-197.61M | $-3.97 |
| 2017 | $2.61M | $-302.14M | $-7.12 |
| 2016 | $133.0K | $-245.87M | $-6.21 |
| 2015 | $0.00 | $-145.62M | $-3.96 |
| 2014 | $0.00 | $-59.80M | $-2.08 |
| 2013 | $0.00 | $-35.07M | $-1.21 |
| 2012 | $0.00 | $-16.33M | $-0.71 |
Valuation
RAREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-24.24%Social Signal Score
Mentions (21)
- Newszacks.com·21h ago·Neutral
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
View source ↗ - Newsprnewswire.com·12d ago·Negative
JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA Selected retained-core intervals contain rare earth elements, including neodymium, praseodymium, terbium and dysprosium (magnet rare earths), together with uranium, vanadium and phosphate mineralization. 0.63 m @ 3,570 ppm TREO (0.357%) and 607 ppm MREO, the highest TREO value reported from the selected intervals in this resampling program.
View source ↗ - Newsglobenewswire.com·14d ago·Negative
ULTRA-RARE MCA CENTENAIRE, MONACO'S FIRST SUPERCAR, OFFERED AT BROAD ARROW'S 2026 ZOUTE CONCOURS AUCTION Monte Carlo Automotive (MCA) Centenaire was the first road car with a carbon fibre monocoque chassis and is powered by a 5.2-litre V12 from the Lamborghini Countach 5000 QV | This example of Monaco's first supercar, created in partnership with Lamborghini, is the first of just five Centenaire models produced | Originally retained by the Lamborghini factory and displayed at Rétromobile 2007, t…
View source ↗ - Newszacks.com·17d ago·Neutral
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
View source ↗ - Newszacks.com·18d ago·Positive
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains? Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A
View source ↗ - Newsreuters.com·18d ago·Negative
US FDA approves Ultragenyx's gene therapy for rare disorder The U.S Food and Drug Administration said on Thursday it has approved Ultragenyx's gene therapy for the treatment of a rare, fatal disease.
View source ↗ - Newszacks.com·32d ago·Neutral
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsbarrons.com·33d ago·Negative
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet. Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains squared on its burgeoning commercial business.
View source ↗ - Newsreuters.com·33d ago·Negative
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial Shares of Ultragenyx Pharmaceutical plunged more than 40% in premarket on Thursday after its neurodevelopmental disorder treatment failed a closely watched late-stage trial, dealing a major blow to one of its biggest growth bets.
View source ↗ - Newsreuters.com·33d ago·Negative
Ultragenyx's rare disease drug fails in late-stage trial; shares plunge Ultragenyx Pharmaceutical said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial, sending its shares down 40% in aftermarket trading.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)
View source ↗ - Newsglobenewswire.com·34d ago·Negative
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease At Week 96, participants across treatment and crossover groups experienced mean reduction in daily cornstarch intake of 61% while maintaining glycemic control, with most participants achieving reduction of at least 50%
View source ↗ - Newszacks.com·46d ago·Positive
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.
View source ↗ - Newsbenzinga.com·47d ago·Negative
Ultragenyx Nabs FDA Nod for First Gene Therapy Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares are up during Thursday's premarket session on the recent U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr, or DTX401).
View source ↗ - Newsmarketbeat.com·47d ago·Negative
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy Ultragenyx Pharmaceutical NASDAQ: RARE said the U.S. Food and Drug Administration has approved GENGLYCOS, also known as DTX401, for glycogen storage disease type 1A, or GSD1A. The approval marks the company's first gene therapy approval and its fifth approved medicine.
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript
View source ↗ - Newsreuters.com·47d ago·Negative
Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod The U.S. Food and Drug Administration approved Ultragenyx Pharmaceutical's gene therapy to treat a rare metabolic disorder, the company said on Wednesday.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultragenyx received a Priority Review Voucher upon approval Ultragenyx to host conference call on 8/19/26 at 6:00 p.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Ultragenyx: Undervalued Ahead Of Two FDA Decisions Ultragenyx Pharmaceutical is rated a soft Buy at $26.75, with a probability-weighted fair value of ~$32 per share. Two near-term FDA decisions: DTX401 on Aug 23 and another for UX111 on Sept 19. DTX401 has a cleaner regulatory case, but UX111 has a credible approval path. Using 80% approval odds for DTX401 and 65% for UX111, our probability-weighted value is approximately $32 per share versus a current share price near $27.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.65 per share
Typical surprise -5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.90 vs $-1.22beat
- Tue, May 5$-1.84 vs $-1.49miss
- Thu, Feb 12$-1.29 vs $-1.20miss
- Tue, Nov 4$-1.81 vs $-1.23miss
- Tue, Aug 5$-1.17 vs $-1.27beat
- Tue, May 6$-1.57 vs $-1.54miss
Estimates and results for RARE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RARE officers and directors.
- Bought
- —
- Sold
- $6.0m
0 trades
39 trades
- Huizenga Theodore Alansold
- Huizenga Theodore Alansold
- Parschauer Karah Herdmansold
- Horn Howardsold
- Horn Howardsold
- Sanders Corazon (corsee) D.sold
- Parschauer Karah Herdmansold
- Horn Howardsold
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2026 (20d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 12, 2025 (35d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 15, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (18d later)Sell$1,001 - $15,000
- Kurt Schraderhouse · OR05 · disclosed Sep 8, 2021 (9d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.